Cortechs.ai Gets FDA Clearance for NeuroQuant PET
Cortechs.ai announced in a press release that NeuroQuant PET received U.S. Food and Drug Administration (FDA) 510(k) clearance for PET. The software aids physicians in evaluating patient pathologies and interpreting PET studies for cognitive impairment and other neurological conditions.
NeuroQuant PET provides automated quantification, regional analysis, and structured reporting for clinical workflows. It supports amyloid PET tracers including flutemetamol, florbetaben, and florbetapir, and generates standardized uptake value ratios and Centiloid measurements.
The platform supports PET CT, PET MR, and PET only workflows. It segments regions of interest and creates outputs prepared for PACS integration.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
AIRS Medical Gets FDA Clearance for MRI Body Composition Tool
INmune Bio and QCi Apply Quantum Computing to XPro Research
Quantiphi Named Leader in NelsonHall Wealth Management Evaluation
FDA Clears Nutshell Therapeutics' NRF2 Degrader NTS231
HOPPR Brings Radiology Foundation Models to CARPL.ai
Daily AI Brief: the AI news that matters, in your inbox.